Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDE574 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT07540572Phase 1Recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Mar 2026
- Primary completion
- Dec 2029
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of IDE574 in solid tumor (4 arms), sponsored by IDEAYA Biosciences. Primary endpoints: Safety and Tolerability, Objective Response Rate and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
IDE574
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07540572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07540572.